The distribution of insertionally polymorphic endogenous retroviruses in breast cancer patients and cancer-free controls by unknown
Wildschutte et al. Retrovirology 2014, 11:62
http://www.retrovirology.com/content/11/1/62RESEARCH Open AccessThe distribution of insertionally polymorphic
endogenous retroviruses in breast cancer patients
and cancer-free controls
Julia H Wildschutte1,4, Daniel Ram2, Ravi Subramanian1, Victoria L Stevens3 and John M Coffin1*Abstract
Background: Integration of retroviral DNA into a germ cell can result in a provirus that is transmitted vertically to
the host’s offspring. In humans, such endogenous retroviruses (HERVs) comprise >8% of the genome. The HERV-K
(HML-2) proviruses consist of ~90 elements related to mouse mammary tumor virus, which causes breast cancer in
mice. A subset of HERV-K(HML-2) proviruses has some or all genes intact, and even encodes functional proteins,
though a replication competent copy has yet to be observed. More than 10% of HML-2 proviruses are human-specific,
having integrated subsequent to the Homo-Pan divergence, and, of these, 11 are currently known to be polymorphic
in integration site with variable frequencies among individuals. Increased expression of the most recent HML-2
proviruses has been observed in tissues and cell lines from several types of cancer, including breast cancer, for
which expression may provide a meaningful marker of the disease.
Results: In this study, we performed a case–control analysis to investigate the possible relationship between the
genome-wide presence of individual polymorphic HML-2 proviruses with the occurrence of breast cancer. For this
purpose, we screened 50 genomic DNA samples from individuals diagnosed with breast cancer or without history
of the disease (n = 25 per group) utilizing a combination of locus-specific PCR screening, in silico analysis of HML-2
content within the reference human genome sequence, and high-resolution genomic hybridization in semi-dried
agarose. By implementing this strategy, we were able to analyze the distribution of both annotated and previously
undescribed polymorphic HML-2 proviruses within our sample set, and to assess their possible association with
disease outcome.
Conclusions: In a case–control analysis of 50 humans with regard to breast cancer diagnosis, we found no
significant difference in the prevalence of proviruses between groups, suggesting common polymorphic HML-2
proviruses are not associated with breast cancer. Our findings indicate a higher level of putatively novel HML-2
sites within the population, providing support for additional recent insertion events, implying ongoing, yet rare,
activities. These findings do not rule out either the possibility of involvement of such proviruses in a subset of
breast cancers, or their possible utility as tissue-specific markers of disease.
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Breast cancer is the most common cancer and second most
common fatal cancer among women in the United States.
In 2014, according to American Cancer Society (ACS)
estimates, 232,670 women will have been diagnosed with
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applies to the data made available in this articfrom this malignancy in the United States [1]. It is the lead-
ing cause of cancer-related death in women of Caucasian,
African-American, Asian, and Native American ethnici-
ties, and is the most common cause of death in Hispanic
women. However, the incidence of breast cancer varies
with respect to ethnic populations, suggesting underlying
genetic, environmental, or lifestyle influences in its devel-
opment and/or progression [1,2].
In recent years there have been significant discove-
ries that have contributed to improved prevention andntral Ltd. This is an Open Access article distributed under the terms of the
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ies of the BRCA1 and BRCA2 genes, identified in multiple-
case family studies in which breast cancer cases were
observed to follow a Mendelian pattern of inheritance [3-5].
Subsequent family-based studies have failed to identify add-
itional genes associated with increased breast cancer risk,
although BRCA1 and BRCA2 account for just 20 to 40%
of familial cancers and about 5% of all breast cancer
cases worldwide [6]. More recently, large-scale genotyp-
ing and genome-wide association (GWA) studies have led
to the identification of other breast cancer susceptibility
loci [5,7-9], which are currently estimated to account for
less than 2 to 10% of disease risk, leaving at least 50% of
breast cancer risk that remains to be explained [10]. Al-
though GWA studies have expanded key areas of breast
cancer research, their nature is inherently self-limiting due
to reliance on single nucleotide polymorphisms (SNPs).
As a result, other sources and types genomic and struc-
tural variation -that are also polymorphic and inherited
in Mendelian fashion- are excluded, including recently
mobile genetic retroelements, leaving the possibility of
their disease association closed to investigation in such
analyses.
More than 8% of the human genome is recognizably
of retroviral origin, representing the remnants of ancient
germline infections from exogenous retroviruses [11]. Dur-
ing an active retroviral infection cycle, the viral genomic
RNA is reverse transcribed into a double-stranded DNA
copy that is then permanently integrated into the host gen-
ome. Thus, the integration of retroviral DNA into a germ
line cell may lead to a provirus that is transmitted vertically
to that host’s offspring as an endogenous retrovirus (ERV)
[12]. If such an integration event has no immediate negative
affect to the host, the provirus may be passed successively
from parent to offspring over generations, eventually gain-
ing population-wide polymorphic persistence and even fix-
ation within the population. The vast majority of human
ERVs (HERVs) were formed from germline infection and
integration tens of millions of years ago, having since be-
come highly mutated and truncated, or recombined to
form solo LTRs, and are thus present without any infec-
tious or functional capacity. However, a small number of
HERVs -particularly those having formed within the last
few million years– have retained at least some coding cap-
acity and many are actively transcribed in certain cancers
as well as some normal tissues [13,14].
The most recent retroviruses to colonize the human
germ line are from the betaretrovirus-like HERV-K
(HML-2) group, most closely related to the exogenous
mouse mammary tumor virus (MMTV) and Jaagsiekte
sheep retrovirus (JSRV), which respectively cause breast
cancer in mice and lung cancer in sheep [15-20]. Within
the human genome, the HML-2 group of proviruses is
represented by approximately 90 proviruses and about1000 solitary LTRs [19]. Unique among HERVs, the HML-
2 group includes at least 23 human-specific proviruses, of
which 11 are currently known to have polymorphic alleles
of varying frequency within the population [16,17,19,20].
Genome-wide and population-based screens have pro-
vided a strong indication for the presence of other unique,
polymorphic HML-2 proviruses within some humans, and
additional insertions are likely to be identified in the near-
future with improved genome sequencing technologies
and population-wide detection strategies; however, re-
search into the patterns and prevalence of such HERVs is
lacking [17,21]. The possibility remains that members of
this group are still capable of replication, either from very
rare but still-active individual proviruses or from the for-
mation of a replication-competent recombinant via com-
plementation of expressed and co-packaged viral RNAs
into a budding particle. In support of this possibility, most
human-specific and all polymorphic HML-2 proviruses
have more than one intact open reading frame (ORF), and
some encode functional proteins and even retrovirus-like
particles (RVLPs) [19,22-27]. Also, the rate of accumula-
tion of HML-2 proviruses in the human genome appears
to have been constant since the Homo-Pan divergence
[21]. Although a naturally occurring HML-2 provirus with
infectious capacity has yet to be observed, engineered con-
sensus HML-2 proviruses are weakly infectious [28,29].
A growing number of reports continues to demon-
strate increased levels of HML-2 transcripts and proteins
in affected tissues from several types human disease, in-
cluding but not limited to ovarian cancer [30], germ cell
tumors [24,31-34], melanomas [35-40], and leukemias/
lymphomas [41,42]. Of particular interest has been
HML-2 proviral expression in diseased tissues associated
with breast cancer, with up-regulation of HML-2 both
from breast tumor biopsies and cell lines derived from
breast tumor tissues [41,43-48]. In matched-tissue ana-
lyses, spliced and unspliced HML-2 env transcripts have
been detected in cancerous breast tissue, but not adja-
cent normal epithelia [43,46,47]. Also, the release of
HML-2-encoded RVLPs associated with encapsidated,
unspliced transcripts and RT activity has been shown for
multiple breast cancer-derived cell lines [49-51]. While
the consequence of endogenous HERV expression is
poorly understood, an essential relationship may be in-
ferred through the genetic association of an inherited
provirus to a particular disease, as is known to occur in
a few animal models, such as the association of certain
MMTV proviruses and mammary carcinoma in mice
[52,53]. Given their variable presence within the popula-
tion and high levels of functional conservation, only the
HML-2 group of HERVs contains representative candi-
dates for such a scenario.
Two HML-2 proviruses, referred to as K113 and K115
(located respectively at chromosomal regions 19p12 and
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ation [54-57]. Present respectively within ~30% and ~15%
of individuals tested, K113 and K115 are estimated to have
integrated into the germline <2mya and have functional
ORFs [19,20,57]. At least one report has investigated the
prevalence of K113 and K115 among breast cancer pa-
tients [54], however the prevalence of other polymorphic
HML-2 proviruses has not been addressed. Furthermore,
the presence of additional unique yet currently unchar-
acterized polymorphic HML-2 proviruses within the popu-
lation [17] makes it difficult to conclusively test for a
genetic association using conventional methods, such
as microarray hybridization or genomic sequencing, which
are essentially blind to the detection such unannotated
genomic variation.
We report the distribution of polymorphic HML-2
proviruses, including elements not previously character-
ized, in a cohort of breast cancer patients and individuals
with no history of the disease. In a combined approach using
PCR screening and ‘unblotting’, or direct hybridization
of DNA within semi-dried agarose, a high-resolution
technique previously developed and used by our lab to
characterize endogenous murine leukemia viruses [14,58],
we investigated the prevalence of individual polymorphic
HML-2 proviruses in a case–control comparison. Al-
though we found no significant difference in the preva-
lence of individual proviruses between groups, suggesting
that common polymorphic HML-2 proviruses (present
in >5% individuals tested) are not associated with breast
cancer. However, these findings do not exclude either the
possibility that rarer HML-2 proviruses are somehow in-
volved in a subset of breast cancers or will provide a
meaningful biomarker of this disease.
Results
Analysis of annotated polymorphic HML-2 proviruses in
breast cancer patients
We first sought to examine the prevalence of the currently
described polymorphic HML-2 proviruses in a case–control
analysis in order to determine whether any was detected
with a strong difference in frequency between groups, and
to provide a direct comparison for the subsequent analysis
of previously uncharacterized polymorphic proviruses. For
these purposes, we screened a panel of genomic DNA sam-
ples from diagnosed breast cancer patients and individuals
with no history of the disease. Samples were generously
provided by the American Cancer Society (ACS) and were
from the Cancer Prevention Study II Nutrition Cohort
(CPS-II). CPS-II is a large-scale study designed to provide a
prospective means for investigating the relationship be-
tween lifestyle factors and exposure risk to cancer inci-
dence, mortality, and survival [59]. We initially analyzed 50
unlinked and de-identified genomic DNA samples from
breast cancer cases or controls (n = 25 per group).Previous work from our lab and by others has led to
the identification of 11 examples of HML-2 proviruses
for which multiple alleles can be detected with varying
frequencies among humans (Table 1) [15-17,19,20]. We
verified the chromosomal locations for 8 of the 11 poly-
morphic proviruses within the February 2009 human
genome build (GRCh37/Hg19), with reference to parallel
BLAT searches against earlier genome builds (March
2006 Hg18; May 2004 Hg17; July 2003 Hg16). For a con-
ventional and consistent nomenclature reference [19], the
proviruses included here are identified by their chromo-
some location and position relative to other proviruses if
multiple proviruses are present within the same chromo-
somal band. The full-length sequences of four elements
are absent from all published builds: two proviruses, lo-
cated at 10p12.1 (also referred to as K103) and at 12q13.2,
are represented as solo LTRs; the 19p12b (K113) inser-
tion site is empty, with no evidence of a polymorphic
provirus at the site; the remaining provirus (referred to as
K105) is integrated within the unassembled centromeric
region Un_g1000219 and unaligned to the current genome
build. However, the genomic regions flanking each integra-
tion site are publicly available (respectively JN675098.1,
JN675106.1, JN675117.1, and JN675176) [19], and
BLAT searches were performed to verify each chromo-
somal location.
Initial HML-2-specific PCR screening was performed
with all CPS-II samples blinded and randomly sorted.
Locus-specific amplification was performed to detect the
alleles present at each HML-2 insertion site, with primers
spanning either the 5’ LTR of each provirus (indicating the
presence of the more or less full-length allele) and span-
ning the integration site (to detect either a solo LTR or
the ancestral pre-integration sequence) (Table 2). Repre-
sentative products from each amplified site were se-
quenced in both directions to confirm the correct product
and to ensure primer specificity (data not shown). Upon
completion of the primary screen, information for the dis-
ease group (breast or prostate cancer) and case/control
identity was unblinded, and the samples sorted and grouped
accordingly. PCR amplification for each HML-2 integration
site was repeated as above to confirm the initial results,
and to provide a direct case–control comparison for the
breast cancer sample group. The frequency of each pro-
virus was calculated per site per group, and the results
subjected to a χ2 analysis, with a p-value of <0.05 regarded
as significant within the dataset. The results are summa-
rized in Table 3.
The majority of HML-2 insertion sites examined had
no significant difference in proviral frequencies between
groups. However from our initial case–control screens,
we observed the K115 provirus to be present at a higher
prevalence within breast cancer cases (6/25, or to a fre-
quency of 0.24) than in the control group (1/25, or
Table 1 Known polymorphic HML-2 proviruses in human DNA
HERV-K notation Locus Start (bp) in Hg19 Allelesb Accession number Reference
1p31.1 75842771 pro AC093156.2 [16]
K106 3q13.2 112743479 pro, solo AC024108.22 [14]
K109 6q14.2 78427019 pro, solo AC164615.1 [14,16]
K108a 7p22.1a 4630561 pro, solo, tandem, pre AC164614.1 [16,26]
K115 8p23.1 8054700 pro, pre AY037929.1 [19]
K103 10p12.1 27182399 pro, solo AF164611.1 [14]
11q22.1 101565794 pro, solo, pre AP000776.5 [16,25]
12q13.2 55727215 pro, solo, pre JN675067 [18,20]
12q14.1 58721242 pro, solo AC074261.3 [16,25]
K113 19p12 21841536 pro, pre AY037928.1 [19]
aK108 is present as a tandem provirus in the published genome with a single shared LTR in the middle. The start coordinate refers to the right provirus of the
tandem pair.
bPro, provirus; solo, solo LTR; pre, pre-integration (empty) site.
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observation was of interest, given the significant differ-
ence in frequency between groups for the sample size.
However, this particular provirus has been previously an-
alyzed for possible association with a few human diseases
(including breast cancer [54]), without significant sup-
port. Thus, we attempted to test the observed differenceTable 2 Primers and product sizes for the detection of polym





















a‘I’ specifies primers for the 5’LTR; ‘II’ specifies primers for either the solo LTR or emp
bProduct sizes were estimated using in silico PCR (UCSC Genome Browser) of prime
were estimated manually by adding the distances to the distance to the nearest Bs
respective provirus for that site.within a larger collection of representative genomic sam-
ples (to >90% statistical power). For this purpose, a unique
set of 200 CPS-II samples (100 breast cancer cases and
100 controls) was analyzed for the presence of K115 alone.
We found that the initial result was not corroborated in
the repeat analysis, in which K115 was observed in 6/100
cases (0.06) and 11/100 controls (0.11) (corresponding toorphic HML-2 proviruses






















r pairs. Product sizes for alleles for the 10p12.1, 12q13.2, and 19p12b proviruses
rI site in the host genome regions flanking each integration site and in the
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suggest that no described individual polymorphic HML-2
provirus is associated with breast cancer occurrence for
the CPS-II genomic samples screened; however these re-
sults do not exclude the possible association of HML-2
occurrence within a subset of breast cancer cases, or other
disease types with implication for involvement.
Of the described polymorphic HML-2 proviruses, most
are present in relatively high allele frequencies within
humans (~50% or above), and even the K113 and K115
proviruses are present in as many as 30% to 40% of
tested individuals, depending on the ethnicity (on average,
within ~16-20% random individuals tested) [20,57]. Aside
from the 11 described polymorphic integration sites, there
is evidence that other unique polymorphic HML-2 pro-
viruses are present in varying frequencies within humans
[14,16,17,20]. However, the population distributions, gen-
omic locations, and any sequence information of such
elements are unknown. Previous work in our lab has
shown that ERVs can be detected from fragmented gen-
omic DNA by utilizing a high-specificity hybridization
technique referred to as ‘unblotting’, during which restric-
tion enzyme digested DNA is hybridized with a radiola-
beled probe while immobilized in semi-dried agarose
following electrophoresis [14,17,58]. Using this technique,
polymorphic integrations can be identified as bands that
vary between samples, and provides the means for direct
comparison between individuals and/or groups. Therefore,
we used unblotting to estimate the total number, distribu-
tion, frequency, and potential disease association of indi-
vidual polymorphic HML-2 proviruses, including known
integrations and those not previously described in the
current genome databases, within our sample set.Table 3 Prevalence of polymorphic HML-2 proviruses in breas
HML-2
Locus
Breast cancer casesa Hea
# Positive Frequency # Po
1p31.1 16 0.64 17
3q13.2 25 1.00 25
6q14.2 21 0.84 23
7p22.1R 25 1.00 25
7p22.1 L 24 0.96 25
8p23.1a 6 0.24 1
10p12.1 24 0.96 25
11q22.1 23 0.92 20
12q13.2 20 0.80 21
12q14.1 23 0.92 22
19p12b 3 0.12 3
aBand sizes are based on estimated fragment lengths; each has been indicated by
bTotal sample size was 50 (n = 25 per group).
*Indicates significance (p > 0.05) within the dataset (not corrected for multiple comIn silico analysis of polymorphic proviruses
Initially, we performed in silico analysis as a means both
to identify appropriate restriction enzymes for unblot
analysis, and to generate predicted fragment patterns of
previously annotated HML-2 proviruses with reference
to the published genome sequence. For these purposes,
we mined the Hg19 genome build for proviruses with
high nucleotide identity to HERV-K113 (19p12b). We
chose this full-length provirus as a reference since it is
completely intact and represents one of the most evolu-
tionarily recent germline integrations [19,20]. Full-length
sequences were extracted for a total of 62 identified pro-
viruses, to which 5 other described proviruses (located
at 10p12.1 (K103), 19p12b (K113), at 12q13.2, and the
K105 provirus located within an unaligned contig,
Un_gl000219 [19] were manually added.
To identify a suitable probe sequence, we aligned and
manually edited the full nucleotide sequences of all 66
proviruses, sorted individual elements in the resulting
alignment by decreasing nucleotide identity to K113, and
searched the alignment for sequence regions that were 1)
highly similar among the most recently integrated ele-
ments (i.e., polymorphic and/or human-specific insertions),
2) distinct from the remaining proviruses, and 3) proximal
to, but not within, the 5’ LTR. We identified a highly con-
served region of about 32 bp within the gag leader region
just outside of the 5’ LTR and ~1 kb from the start of
the HML-2 consensus sequence (Figure 1). BLAT searches
for this sequence returned 25 hits, all of which corre-
sponded to HML-2 proviruses; 17 were identical to the
queried 32 bp sequence, and 8 had two or fewer mis-
matches (Figure 1). Of note, the matching sequences
included all described human-specific proviruses thatt cancer
lthy controlsa












arrow in Figure 2.
parisons).
Figure 1 Identification of a conserved sequence for the detection of recently integrated HML-2 proviruses. A BLAT search of the 2009
human genome sequence build GRCh37/Hg19 for the ~32 bp K-seq sequence (shown in box) returned each provirus included in the alignment.
The aligned sequences have been ordered with reference to percent identity to the K113 nucleotide sequence to depict the conservation of the
region among the most recently formed germline integrations. Bases shared with K113 are indicated as dots, and differences are indicated by the base
present at that site. Asterisks at left indicate A. human-specific and B. polymorphic proviruses; C. predicted fragment sizes (in bp) based on restriction
analysis of the published human genome (Hg19); D. reference aliases of each provirus; E. chromosomal locus of each analyzed element.
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support for the specificity of the probe. We therefore took
advantage of this sequence, referred to here as ‘Kseq’, for
in silico restriction fragment analyses and subsequent
DNA hybridizations to facilitate detection of the most
conserved HML-2 proviruses present within our sampled
genomes.
An in silico restriction analysis for the Hg19 human
reference genome build was performed to identify candi-
date restriction enzymes for hybridization of the Kseq
site within sampled human genomes. Each of the 25 ele-
ments identified by BLAT of the Kseq region was simul-
taneously analyzed for enzymes predicted to cut at least
once within the provirus but not within the 5’LTR, as
well as for the nearest restriction site within the host
flanking DNA. As a result, each Kseq-containing ‘frag-
ment’ is predicted to contain a single proviral junction
site, whereas the size of each fragment is defined by the
distance from the first cleavage site 3’ of the probe site
to the nearest restriction site in host DNA (Figure 1,
upper). Of about 35 candidate enzymes, 6 were analyzed
in preliminary unblot screens using DNA from the
T47D breast tumor-derived cell line (data not shown),
and BsrI was finally selected for further hybridizationscreening with reference to overall fragment size distri-
butions (ranging from ~1 kb- > 6 kb) and total number
of fragments predicted to contain HML-2 proviral junc-
tion sites (as many as 30; discussed further below). The
BsrI fragment distribution, as predicted from the Hg19
human reference build, is shown for reference in
Figure 2A.
Case–control analysis of polymorphic HML-2 proviruses in
breast cancer
Based on in silico predictions, we utilized unblotting [14,58]
to infer the distribution of polymorphic HML-2 provi-
ruses within the genomes of the CPSII subjects. The
unblotting technique is similar to Southern blotting
DNA hybridization, but omits the transfer step of the
DNA template, and consequently offers increased reso-
lution without the loss of target DNA. A caveat is that at
least 10 μg of template is required per sample per run,
thus challenging the examination under conditions of lim-
ited quantities of genomic DNA, as was for the CPS-II
samples (~1 μg per sample). We therefore subjected each
sample to whole genome amplification (WGA; REPLI-g
MIDI kit, Qiagen) step to generate working amounts
of DNA per sample (at least 15 μg in our hands).
Figure 2 Distribution of polymorphic HML-2 proviruses in breast cancer cases and controls. A. Comparative schematic representing the
in silico-predicted sizes for HML-2 containing fragments following BsrI digestion and detected by the K-seq probe within the Hg19 genome build.
Asterisks at left indicate the confirmed polymorphic proviruses, whose distribution coincides exactly between unblot banding patterns and PCR
data. B. CPSII samples were sorted by case/control status (n = 25 each) and BsrI digested WGA-DNA from each group was separated by gel
electrophoresis and probed with the 32P-radiolabeled K-seq oligonucleotide. HML-2 junction fragments were visualized following exposure to film,
and polymorphic insertions inferred by variable banding patterns among samples. C. Results from PCR analysis of known polymorphic proviruses
for direct comparison of described polymorphic elements, where ‘+’ indicates the confirmed presence of the tested provirus. Novel polymorphic
fragments whose identity could not be inferred by comparison to PCR analysis or in silico predictions, have been indicated with arrows at right.
Asterisks (at right) are used to indicate the observed fragment sizes of polymorphic elements detected in ≤5% individuals screened here.
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and the products separated by electrophoresis through
agarose. Simultaneous treatment of genomic DNA ex-
tracted from the T47D breast tumor-derived cell line was
used as a control. The agarose was then dehydrated and
the immobilized DNA hybridized with a 32P-labeled
oligonucleotide complementary to the Kseq sequence,
and finally exposed to film to visualize the prevalence
and distribution of detectable HML-2-containing frag-
ments. As with the initial HML-2-specific PCR screens of
described polymorphic proviruses, all preliminary unblots
were performed while samples were blinded, and follow-
ing the subsequent release of their case/control status, the
ublotting was repeated on a case–control basis and the
samples analyzed by direct comparison between groups.
Consistent with the cognate in silico analysis of the Hg19
human reference, unblots were interpreted such that
each detected fragment represented a single proviral junc-
tion site, the size of which was dependent on the length
of host sequence to the nearest 5’ flanking restrictionsite. The resulting unblots are shown by case/control group
in Figure 2B.
Overall, the banding patterns we observed by unblot
of WGA-DNA were in close agreement with those pre-
dicted by in silico restriction analysis of the Hg19 genome
build (Figure 2A and B), implying uniform amplification
of all regions of the DNA. On average, we observed be-
tween 18 and 22 bands per lane in fragments that varied
from sample to sample. To further characterize the frag-
ments observed to be polymorphic among individuals,
we compared the distribution of polymorphic HML-2
proviruses with that of previously described copies, as
interpreted by PCR screen. Comparison between HML-2-
derived unblotting and PCR data allowed for the provisional
assignment of a few fragments based on shared distribu-
tion between each analysis, each of which was further sup-
ported in agreement with the corresponding in silico
predicted sizes (asterisks in Figure 2A). Most clearly rep-
resented were the fragments predicted to represent the
11q22.1 5’LTR junction, with a band around 2.1 kb that




# Positive Frequency # Positive Frequency χ2 p-value
4600 25 1.00 22 0.88 3.19 0.07
3700 10 0.40 11 0.44 0.08 0.78
3200 1 0.04 4 0.16 2.00 0.16
1500 25 1.00 23 0.92 2.08 0.15
1470 8 0.32 5 0.20 0.93 0.33
aBand sizes are based on estimated fragment lengths; each has been indicated by arrow in Figure 2.
bTotal sample size was 50 (n = 25 per group).
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all samples as determined by PCR (Figure 2B). Also near
the 1.7 kb size, hybridized fragments were 100% consistent
with the in silico size prediction and PCR distribution of
the 12q14.1 provirus. Finally, we observed fragments
matching the PCR distribution and size predictions of the
12q13.2 and K115 proviral junctions around 2.3 kb and
2.5 kb, respectively. At least two of the hybridized frag-
ments (located at 11q22.1 and 12q13.2) could be unam-
biguously assigned to the corresponding HML-2 provirus
by locus-specific amplification and sequencing of their
5’LTRs and host flanking regions from template DNA ob-
tained by elution from the corresponding unblotted gel re-
gions (data not shown).
For the remaining known polymorphic HML-2 provi-
ruses, discrimination of their specific locus was less clear
by comparison with previous PCR analysis in conjunction
with in silico predictions. A few such elements were fixed
or nearly fixed within the sample set as indicated by
locus-specific PCR, for example the proviruses located at
3q13.2 and 7p22.1b, thus complicating their assignment,
however all CPSII samples were observed to have hybrid-
ized fragments near the predicted sizes of these elements
(respectively 1985 bp and 1981 bp; also refer to Table 2).
The expected banding patterns for the 1p31.1 and 6q14.1
elements could not be discerned by 5’ LTR amplification,
although the predicted junction fragments are around
1.7 kb (1751 for 1p31.1 and 1758 for 6q14.1). Given the
number of bands that were both predicted and observed
to fall within approximately the same size range, their spe-
cific banding patterns are likely to have been obscured.
Another possibility is that some provirus-containing frag-
ments may have been ‘lost’ due to the variable presence of
common sequence polymorphisms within a meaningful
Bsr1 site, or from sample-specific genomic structural vari-
ation in regions associated with HML-2 insertions; either
scenario could potentially result in a junction fragment of
an unexpected or undetectable size. Although this possi-
bility cannot be excluded, we note the remaining predicted
polymorphic HML-2 proviruses were consistent and well-
supported among all results from unblotting, PCR screen-
ing, and in silico restriction analysis.To identify putatively novel integration sites, we exam-
ined each unblot for polymorphic bands that were neither
predicted by in silico analysis of the described HML-2
polymorphic proviruses within the available databases,
nor consistent with any distribution observed by direct
PCR analysis. Several fragments, with estimated sizes from
1.4 to 4.6 kb, were identified that met these criteria; these
particular HML-2-containing fragments were clearly vis-
ible within multiple samples from either group, varying in
frequency from ~0.02 to 0.98. One such band of interest,
specifically in lane 25 of the control group at ~1.4 kb, was
represented by a single band not observed in any other
sample, whereas the opposite was observed for other frag-
ments, for example the band visible around ~5.5 kb, which
was present in the majority of samples (each example is
indicated by an asterisk near the relative fragment size in
Figure 2B, right). In all, roughly 5–10 polymorphic bands
were visible, and of those, about 5 were clearly discernable
across the total CPSII sample set (indicated in Figure 2B
by arrows at right) The individual frequencies for each
such fragment were directly compared between cases and
controls by χ2 analysis (Table 4). Consistent with the initial
PCR based analysis of described polymorphic elements as
described above, no observed fragment differed signifi-
cantly in its distribution between groups. The results indi-
cate that at least within this sample set, polymorphic
HML-2 proviruses do not imply association of a risk of
breast cancer. However, our results also draw attention to
an unexpected level of HML-2 content among these rela-
tively few genomes tested in the present analysis.
Discussion
A few endogenous proviruses are known as causative to
disease in experimental animal model systems, including
the Betaretrovirus MMTV and mammary carcinoma in
mice [15-20]. A similar association of the HML-2 provi-
ruses, closely related to MMTV, is yet to be established,
and remains a topic of study in the field. Here, we
present our analysis of the distribution and prevalence
of polymorphic HML-2 proviruses within the genomes
of subsequently diagnosed breast cancer patients and
from individuals with no history of the disease. For these
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first developed a locus-specific PCR strategy to determine
and assess the prevalence of each currently annotated
polymorphic HML-2 locus with reference to the human
reference database, as well as detection of the cognate
unoccupied pre-integration sites and/or solo-LTR, where
applicable. Secondly, we utilized unblotting, a high reso-
lution and highly sequence-specific genome hybridization
technique, as a means to provide direct inference of the
prevalence and group distribution of putatively novel
HML-2 polymorphic proviruses among the sampled ge-
nomes. For such proviruses, virtually nothing is known in
terms of integration site, proviral structure, or functional
features. To out knowledge, this is the first and most thor-
ough report of such a comparison, and by far the largest
representative set of human genomes analyzed for unchar-
acterized polymorphic proviruses from the most recently
active HERV group.
The K113 and K115 proviruses were the first poly-
morphic HML-2 members to be discovered for which
the empty-pre-integration site was still present within
the population, and for which the proviral alleles were at
relatively low frequencies, implying relatively recent
germline integration (roughly estimated at <200,000 years
and ~1.2 mya, respectively) [20]. In multiple reports, spe-
cific attention has been given to these two proviruses as
possible candidates for roles in human diseases, including
breast cancer [54], multiple sclerosis [56,57], schizophre-
nia [60], and autoimmune diseases [55,57]. Two of these
reports are worth noting, in the context of the results pre-
sented here. In 2005, Moyes et al. [57] reported a “signifi-
cantly” higher prevalence of the K113 provirus in the
genomes of 109 multiple sclerosis patients. However, the
analysis included multiple comparisons in terms of both
proviruses tested and number of disease states, and the as-
sociation was not replicated in a larger scaled study specif-
ically addressing K113 prevalence and multiple sclerosis
[56], highlighting the importance of being able to test such
an initial finding on a statistically supported scale. Also
pertinent is the 2004 report from Burmeister et al., in
which K113 was observed at a somewhat higher frequency
in individual breast cancer patients from an initial screen
of 102 patients’ genomes [54]. This particular result lacked
statistical significance and was not further tested in larger
screens. In the present study, our initial observation of a
higher prevalence of the K115 provirus to breast cancer
cases was not replicated in an independent set of samples,
which we were fortunate to have been made available to
us through the ACS CPSII Nutrition Cohort Study. Given
the negative outcome of the PCR analysis of the second,
larger sample set, the necessity for such added analysis is
made clear.
In previous investigations for evidence of disease asso-
ciation, frequencies of the K113 and K115 proviruseshave been reported to range from ~10-20% for K113
and ~5-12% for K115 [20]. Our results are consistent
with these observations, with the exception of the K115
provirus in ~24% of cases in the initial screen (Figure 2B
and C). This frequency is not completely unexpected,
however, as values as high as >40% have been reported,
depending on the race of the samples tested [20,57].
Similarly, in other analyses the K113 provirus has been
observed at levels as high as ~30%, again depending on
race [20,57]. Given such variance, the observed frequen-
cies of the K115 provirus among DNAs from breast can-
cer cases may reflect an uneven representation with
regards to ethnicity in the sample set. Alternatively, the
higher frequency of K115 we observed in cases could be
due to stochastic effects from the relatively small sample
size used for the present analysis. As the samples were
de-identified, we can only speculate on the factors, if
any, influencing the observed distribution.
To date, all reports that have attempted to detect a
genetic association of individual HML-2 proviruses have
had a predominant focus to K113 and K115, given their
status as the most recently integrated and conserved
HML-2 loci known, however their analysis (over several
diverse populations and disease groups) have offered little
support for any implications in disease. This is perhaps
not surprising, as a provirus that did have negative effects
to the host would have a much reduced probability of
population fixation, or would likely be removed from the
population by selection. Thus, those proviruses with rare
frequencies among humans would be more appropriate
candidates for inference of disease-associated loci. The de-
tection of such elements will necessitate much larger sam-
ple sizes than have been used to date, including the analysis
presented here. Repeated searches for a disease association
with one or two particular elements alone, such as has been
the case for the K113 and K115 proviruses, will likely have
similar outcomes as have been observed. We attempted to
overcome such limitations by screening human genomes
from the CPS-II ACS Nutritional Cohort using a highly
specific DNA hybridization in a case-control comparison;
we interpret our data to indicate the detectable presence
of several as-yet-uncharacterized polymorphic proviruses,
though none infer genetic association to disease.
We note that, although “new” bands observed from the
unblots have a high likelihood of representing HML-2
containing genomic fragments, they may not reflect previ-
ously undescribed proviruses. For example, they could
possibly have been a consequence of single base changes
in known proviruses that destroyed or created a target
sequence for BsrI restriction enzyme cleavage, Further-
more, the absence of certain bands in some samples could
result from known full-length proviruses that have recom-
bined to form solo LTRs in some individuals, or from
recombination-mediated structural variation with reference
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in our approach. Also, a point mutation could lead to the
generation of a new restriction site, for example within the
5’ LTR, that would prevent the detection of the corre-
sponding junction fragment by the probe. We searched for
such an example from the fragments that we could tenta-
tively identify as described HML-2 (asterisks in Figure 2A),
and found the PCR and unblot data were in agreement,
giving support that the BsrI target sites for these particu-
lar elements have not been disrupted. However, with-
out knowledge of the chromosomal site of integration for
each detected fragment, it is difficult to exclude the possi-
bility of mutation (or possibly common SNPs among
subjects) having occurred at restriction sites proximal to
other detected proviruses.
In this study, we have developed an approach to identi-
fying novel polymorphic proviruses in human populations,
starting with samples of nanogram quantities of DNA,
and we have provided evidence for a number of poly-
morphic proviruses that vary in frequency among the
samples tested, some of which are present at quite low fre-
quencies (for example, in lane 25 of the ‘undiagnosed con-
trols’ in Figure 2B, asterisk at right). For the ~50 genomic
DNAs in this analysis, between 18 and 22 bands were ob-
served per sample. In the total set, there were about 10-15
junction fragments for which a corresponding known
provirus could not be inferred from comparison to in
silico or PCR analyses. Given the sample size, it is likely that
at least some of these HML-2-containing fragments repre-
sent recent bona fide proviral integrations, which are
present in just a portion of individuals, as would be pre-
dicted for such sites. At least two fragments, of sizes around
2.2 kb (in undiagnosed controls, sample 20) and 1.3 kb
(same group, sample 25) (also asterisked in Figure 2B, right)
appear to be present in less than ~5% of the total number
of samples –a far lower representation than seen for any
other described polymorphic provirus or previous report
[16,17]. If not represented by solo LTRs in other individ-
uals, such a provirus is likely to have been recently inte-
grated and to closely resemble the original infecting virus,
and, we can speculate, might also exhibit retained compe-
tency for replication. Current and future efforts to identify
and characterize such novel proviruses will likely help in
clarification of disease and/or phenotypic association of
such sites.
Conclusions
In this study, we investigated the possible relationship be-
tween the genome-wide presence of polymorphic HML-2
proviruses in 50 humans with regard to breast cancer diag-
nosis. Although preliminary PCR analysis indicated the
possibility of an elevated prevalence of one particular pro-
virus, K115 (located at 8p23.1), in cases compared to con-
trols and supported in in DNA hybridization screening,the observation was not replicated to a statistically signifi-
cant level. Thus, we find no difference in the prevalence of
proviruses between groups, suggesting that common poly-
morphic HML-2 proviruses are not associated with breast
cancer in the tested individuals. These findings do not
exclude either the possibility that rare HML-2 proviruses
are involved in a subset of breast cancers, or their possible
utility as tissue-specific expression and/or HML-2-derived
products as potential marker(s) of disease. Interestingly,
our findings do indicate a relatively high level of putatively
novel HML-2 sites within the population, providing sup-
port for additional relatively recent insertion events and
implication for ongoing activities. With continued im-
provements in sequencing technologies and in the de-
tection of such elements, it is likely novel HML-2
polymorphic loci will be identified in the near-future;
their genome-wide implications in terms of population-
level structural variation and/or outcome phenotypic ef-
fects will remain, until then, to be seen.
Methods
Human DNA samples
Human genomic DNA samples were from the ACS Cancer
Prevention Study II Nutrition Cohort (CPS-II), a prospect-
ive study of cancer incidence of approximately 184,000
Americans [59]. Nutrition Cohort participants, who were
from 21 states and ranged from 50 to 74 years old at en-
rollment in 1992 or 1993, completed a mailed question-
naire that included questions on demographics, diet, and
other lifestyle factors. Incident cases reported via ques-
tionnaire response were verified through medical records,
linkage with state cancer registries, or death certificates.
Blood samples were collected from a subset of Nutrition
Cohort participants (21,965 women and 17,411 men) be-
tween June 1998 and June 2001, fractionated and stored in
liquid nitrogen vapor phase at −130°C until needed for
analysis. All aspects of the CPS-II Nutrition Cohort study
were approved by the Emory University Institutional Re-
view Board (Atlanta, GA). Original CPS-II samples pro-
vided by the ACS were 100 total: 50 samples were from
participants who were later diagnosed with breast cancer,
and controls (n = 25 per group); 50 samples were from
participants who were later diagnosed with prostate can-
cer, and controls (also 25 per group). Controls were from
participants who were cancer free at the time of diagnosis
of the matching case. Samples were blinded, and subse-
quently unblinded following initial PCR analyses. All sam-
ples were deidentified, with information limited to case/
control assignment. To account for multiple compari-
sons, secondary PCR screens were performed with an
additional 200 genomic DNA samples from the CPS-II co-
hort (n = 100 per breast cancer cases or controls). As
above, all samples were deidentified, and case/control in-
formation unblinded following PCR screening.
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To obtain sufficient DNA for unblotting and PCR ana-
lyses, individually screened CPS-II DNA samples (~1 μg)
were subjected to whole genome amplification (WGA).
WGA was carried out according the manufacturer’s
protocol (MIDI Repli-G, Qiagen) with a starting volume
of 5 μL. Briefly, ~40 ng genomic DNA per sample was de-
natured and neutralized using the supplied buffers in vol-
umes of 5 μL and 10 μL, respectively, for 3 min each at
room temperature (RT). A mixture containing buffered
φ29 polymerase (MIDI Repli-G, Qiagen) and random hex-
amers was added to each sample for a final volume of
50 μL and the samples incubated 16 hr. at 30°C. Amplified
DNA was extracted using 2 mL heavy phase-lock gel tubes
(5 PRIME) in 200 μL volumes according to the manufac-
turer’s protocol. DNA was precipitated from the aqueous
phase in 95% ethanol + 100 mM NaOAc, pH 5.2 to a final
volume of 1 mL and incubated overnight at -20°C. The
WGA DNA was pelleted at 14,000 rpm for 30 min. at 4°C,
washed in 1 ml cold 70% ethanol, the centrifugation re-
peated, and the ethanol carefully aspirated. Pellets were
dried 30 min. at 37°C, resuspended in 100 μL sterile
water, and the WGA DNA measured using a NanoDrop
spectrophotometer.
PCR amplification
For 11 loci with evidence of multiple alleles including
the provirus form, locus-specific primers were de-
signed to amplify the 5’ LTR of the provirus at each site
using the most recently updated human genome Hg19
reference build (Table 1). For each locus, a primer was
designed within ~2 kb of the provirus edge within the
flanking DNA of the host, and a second primer within
the proviral leader sequence, outside of, but near, the
5’ LTR. A third primer was designed in the host DNA
downstream of the integration site in order to detect
and differentiate the remaining alleles, including solo
LTRs and unoccupied integration sites. Primers were
designed using Primer3 v.0.4.0 and obtained from IDT,
unless otherwise noted. An in silico PCR (UCSC Genome
Browser) was used to estimate target amplification and
product size for each primer pair, as provided in Table 1.
All PCRs were carried out using ~200 ng WGA DNA as
template with 1.5-2.5 μM Mg++, 200 μM dNTPs, 0.2 μM
each primer, and 2.5 U Platinum Taq Polymerase (Invitrogen).
10 uL of each PCR reaction were analyzed by electrophor-
esis through 1% agarose in 1 × TBE. Products from 2 separ-
ate positive PCR reactions per primer set were sequenced
to confirm the desired product.
In silico restriction analysis
We used an in silico approach to identify useful restriction
enzymes for subsequent DNA hybridizations to visualize
HML-2 proviruses, and to generate a restriction fragmentcomparison from existing genome sequence data for refer-
ence during unblotting (see below). The HERV-K113 se-
quence (AY037928) was analyzed for restriction enzymes
predicted to cut at least once within the provirus but not
within the 5’LTR (NEBCutter2.0), for a total of 36 candi-
date enzymes. Simultaneously, we mined the 2009 human
genome build (GRCh37/hg19) for proviruses with high
percent identity to HML-2, again using the K113 nucleo-
tide sequence as a reference. For the 32 proviruses identi-
fied from the search, we performed an in silico restriction
analysis as follows. About 5 kb of sequence was extracted
in both directions from the start of the 5’LTR. Each se-
quence was ‘digested’ in NEBCutterV2.0 for each of the
36 restriction sites with reference to a highly conserved se-
quence spanning bases 1017 to 1049 (5’ CGTCGACTTC
TTGTCCTCAATGACCACGC; HERVK-1017). For each
enzyme analyzed, the estimated sizes for predicted HERV-
K-containing junction fragments were plotted on a log
scale for comparison. Based on restriction fragment esti-
mates with reference to genome coverage and the ob-
served fragment distribution, BsrI was selected for unblot
analysis and coordinate in silico comparison to the pub-
lished sequence.
Unblotting
Unblotting, or hybridization in semi-dried agarose [14,58],
was carried out to visualize polymorphic HERV-K provi-
ruses within DNA samples. For each sample, 15 μg of
WGA DNA was digested with BsrI (New England Biolabs)
in a 100 μL volume and the digested products extracted
and precipitated as described above. Products were resus-
pended in 20uL 0.25 x TBE + 30% Ficol and electropho-
resed through a 0.8% agarose gel in 0.25 × TBE at 70 V for
29 hr. at 4°C. The gel was dehydrated in a vacuum dryer
(BioRad) layered on filter papers for 60 min. at RT and
60 min. at 62°C. The dried gel was stained with ethidium
bromide in 0.25× TBE and excess agarose removed with a
clean scalpel. The gel was then incubated in denaturing
buffer (0.5 M NaOH+ 1.5 M NaCl), and neutralizing buf-
fer (1.0 M Tris–HCl + 1.5 M NaCl, pH 8.0) 30 min. each
at RT, and then hybridized with 7.5 × 106 cpm of a 32P-
labeled HERVK-1017 HML-2-specific oligonucleotide.
Hybridization was in 5 mL of 5× SSPE (3.0 M NaCl,
0.2 M NaH2PO4, and 0.02 M EDTA, pH 7.4) + 0.1%
SDS, pH 7.4 at 53°C for 16 hr with shaking at 50 rpm.
Following hybridization, the gel was washed (2× SSC +
0.1% SDS) 4× for 15 min. each at RT, and 2× for 30 min.
each at 53°C with shaking at 70 rpm. The gel was then ex-
posed to BioMax MS film (Kodak) under an intensifying
screen for 4–5 days at −70°C.
Statistical analyses
Frequencies of individual sites were analyzed between
case/control groups by χ2 analysis with one degree of
Wildschutte et al. Retrovirology 2014, 11:62 Page 12 of 13
http://www.retrovirology.com/content/11/1/62freedom. For these analyses, comparisons were between
cases and controls for individual polymorphic proviruses,
calculated from 50 total samples (25 breast cancer per
group). A p value of less than 0.05 was taken to be signifi-
cant. Total numbers of samples for scaled screening were
determined by power analysis. For K115, to replicate a
20% difference between test groups with an α = 0.05, a
statistical level of 80% power requires a sample size of n =
94 (47 per cases and controls), and for 90% power a total
sample size of n = 124 (62 each group). All statistical ana-
lyses were performed by the Data Design and Resource
Center at Tufts University.
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